At #UEGWeek 2026, PCE engaged visitors in conversations about our European projects, including #DISCERN, which investigates the causes of pancreatic, renal and colorectal cancers and why their incidence varies across Europe. #PancreaticCancer
November 2, 2026 at 12:03 PM
At #UEGWeek 2026, PCE engaged visitors in conversations about our European projects, including #DISCERN, which investigates the causes of pancreatic, renal and colorectal cancers and why their incidence varies across Europe. #PancreaticCancer
Beyond the congress: Bringing liver health into the community 💚
At #UEGWeek 2026 in Barcelona, we joined forces with EASL to bring its Love Your Liver initiative to the congress for the first time.
🔗 Read more about the initiative: https://ueg.eu/a/393
At #UEGWeek 2026 in Barcelona, we joined forces with EASL to bring its Love Your Liver initiative to the congress for the first time.
🔗 Read more about the initiative: https://ueg.eu/a/393
October 26, 2026 at 10:05 AM
Beyond the congress: Bringing liver health into the community 💚
At #UEGWeek 2026 in Barcelona, we joined forces with EASL to bring its Love Your Liver initiative to the congress for the first time.
🔗 Read more about the initiative: https://ueg.eu/a/393
At #UEGWeek 2026 in Barcelona, we joined forces with EASL to bring its Love Your Liver initiative to the congress for the first time.
🔗 Read more about the initiative: https://ueg.eu/a/393
🗣️ ACCU España ha estado presente en #UEGWeek, uno de los congresos internacionales de gastroenterología más destacados
El Barómetro BAREII, que recoge la experiencia de las personas con EII, ha formado parte del congreso a través de un póster científico 📊
Leer más 👉 accuesp.com/bareii/
El Barómetro BAREII, que recoge la experiencia de las personas con EII, ha formado parte del congreso a través de un póster científico 📊
Leer más 👉 accuesp.com/bareii/
October 24, 2026 at 1:51 PM
🗣️ ACCU España ha estado presente en #UEGWeek, uno de los congresos internacionales de gastroenterología más destacados
El Barómetro BAREII, que recoge la experiencia de las personas con EII, ha formado parte del congreso a través de un póster científico 📊
Leer más 👉 accuesp.com/bareii/
El Barómetro BAREII, que recoge la experiencia de las personas con EII, ha formado parte del congreso a través de un póster científico 📊
Leer más 👉 accuesp.com/bareii/
🥇🥼El Dr. Manuel Barreiro de Acosta, del grupo Investigación Traslacional en Enfermedades del Aparato Digestivo del #IDIS, gana el Best Abstract Presentation Prize en la #UEGWeek por un estudio pionero para tratar la enfermedad de Crohn realizado en el IDIS-CHUS de Santiago
⬇️
⬇️
October 23, 2026 at 10:42 AM
Our own Dr. Gil Melmed representing Cedars-Sinai at #UEGWeek 2026 in Barcelona 🌍 He presented our IBD prehabilitation cost data — showing that low-cost pre-surgical interventions significantly reduce postoperative costs and readmissions for #IBD patients. So proud! #CrohnsDisease #UlcerativeColitis
October 21, 2026 at 9:09 PM
Our own Dr. Gil Melmed representing Cedars-Sinai at #UEGWeek 2026 in Barcelona 🌍 He presented our IBD prehabilitation cost data — showing that low-cost pre-surgical interventions significantly reduce postoperative costs and readmissions for #IBD patients. So proud! #CrohnsDisease #UlcerativeColitis
AI is already changing digestive healthcare – what comes next?
From polyp detection to emerging AI agents, explore #UEGWeek Opening Plenary presenter Professor Jakob Nikolas Kather’s insights on the opportunities ahead and what safe implementation will take 🔎
From polyp detection to emerging AI agents, explore #UEGWeek Opening Plenary presenter Professor Jakob Nikolas Kather’s insights on the opportunities ahead and what safe implementation will take 🔎
October 22, 2026 at 9:00 AM
AI is already changing digestive healthcare – what comes next?
From polyp detection to emerging AI agents, explore #UEGWeek Opening Plenary presenter Professor Jakob Nikolas Kather’s insights on the opportunities ahead and what safe implementation will take 🔎
From polyp detection to emerging AI agents, explore #UEGWeek Opening Plenary presenter Professor Jakob Nikolas Kather’s insights on the opportunities ahead and what safe implementation will take 🔎
Reducing long-term PPI use – how do three deprescribing strategies compare?
🎤 #UEGWeek top abstract awardee Janne Scheepers takes us through the PEPPER trial’s results, revealing similar success rates across the approaches.
Watch for the key takeaways.
🎤 #UEGWeek top abstract awardee Janne Scheepers takes us through the PEPPER trial’s results, revealing similar success rates across the approaches.
Watch for the key takeaways.
October 21, 2026 at 10:00 AM
Reducing long-term PPI use – how do three deprescribing strategies compare?
🎤 #UEGWeek top abstract awardee Janne Scheepers takes us through the PEPPER trial’s results, revealing similar success rates across the approaches.
Watch for the key takeaways.
🎤 #UEGWeek top abstract awardee Janne Scheepers takes us through the PEPPER trial’s results, revealing similar success rates across the approaches.
Watch for the key takeaways.
Fewer flares, less need for glucocorticoid rescue therapy.
At #UEGWeek, the Phase 3 INDIGO trial found that obexelimab reduced flare risk by 56% compared with placebo in adults with IgG4-related disease, with more patients achieving complete remission.
Take a closer look 🔍
At #UEGWeek, the Phase 3 INDIGO trial found that obexelimab reduced flare risk by 56% compared with placebo in adults with IgG4-related disease, with more patients achieving complete remission.
Take a closer look 🔍
October 20, 2026 at 1:00 PM
Fewer flares, less need for glucocorticoid rescue therapy.
At #UEGWeek, the Phase 3 INDIGO trial found that obexelimab reduced flare risk by 56% compared with placebo in adults with IgG4-related disease, with more patients achieving complete remission.
Take a closer look 🔍
At #UEGWeek, the Phase 3 INDIGO trial found that obexelimab reduced flare risk by 56% compared with placebo in adults with IgG4-related disease, with more patients achieving complete remission.
Take a closer look 🔍
Hear from #UEGWeek top abstract awardee Nurulamin Noor as he discusses the PROFILE findings showing less need for surgery and less disease progression with early top-down anti-TNF therapy versus conventional step-up treatment in Crohn’s disease.
▶️ Watch the full interview.
▶️ Watch the full interview.
October 20, 2026 at 3:00 PM
Hear from #UEGWeek top abstract awardee Nurulamin Noor as he discusses the PROFILE findings showing less need for surgery and less disease progression with early top-down anti-TNF therapy versus conventional step-up treatment in Crohn’s disease.
▶️ Watch the full interview.
▶️ Watch the full interview.
Could a shorter antibiotic course be enough for acute cholangitis? 🎤
Hear from #UEGWeek top abstract awardee Anouk Overdevest about the COBRA trial comparing 1 day with 4–7 days of antibiotics after adequate biliary drainage.
Watch her interview to learn more.
Hear from #UEGWeek top abstract awardee Anouk Overdevest about the COBRA trial comparing 1 day with 4–7 days of antibiotics after adequate biliary drainage.
Watch her interview to learn more.
October 20, 2026 at 11:00 AM
Could a shorter antibiotic course be enough for acute cholangitis? 🎤
Hear from #UEGWeek top abstract awardee Anouk Overdevest about the COBRA trial comparing 1 day with 4–7 days of antibiotics after adequate biliary drainage.
Watch her interview to learn more.
Hear from #UEGWeek top abstract awardee Anouk Overdevest about the COBRA trial comparing 1 day with 4–7 days of antibiotics after adequate biliary drainage.
Watch her interview to learn more.
A meaningful advance for patients with IgG4-related disease.
Hear from top abstract awardee Emma Culver at #UEGWeek on how obexelimab reduced flares and the need for glucocorticoid rescue therapy in the Phase 3 INDIGO trial 🎥
Hear from top abstract awardee Emma Culver at #UEGWeek on how obexelimab reduced flares and the need for glucocorticoid rescue therapy in the Phase 3 INDIGO trial 🎥
October 19, 2026 at 3:30 PM
A meaningful advance for patients with IgG4-related disease.
Hear from top abstract awardee Emma Culver at #UEGWeek on how obexelimab reduced flares and the need for glucocorticoid rescue therapy in the Phase 3 INDIGO trial 🎥
Hear from top abstract awardee Emma Culver at #UEGWeek on how obexelimab reduced flares and the need for glucocorticoid rescue therapy in the Phase 3 INDIGO trial 🎥
Which approach offers safer biliary drainage?
See the #UEGWeek findings from “Primary percutaneous stenting versus endoscopic drainage for unresectable malignant hilar biliary obstruction: a multicenter randomized controlled trial, the TESLA RCT” 🔎
See the #UEGWeek findings from “Primary percutaneous stenting versus endoscopic drainage for unresectable malignant hilar biliary obstruction: a multicenter randomized controlled trial, the TESLA RCT” 🔎
October 20, 2026 at 5:00 PM
Which approach offers safer biliary drainage?
See the #UEGWeek findings from “Primary percutaneous stenting versus endoscopic drainage for unresectable malignant hilar biliary obstruction: a multicenter randomized controlled trial, the TESLA RCT” 🔎
See the #UEGWeek findings from “Primary percutaneous stenting versus endoscopic drainage for unresectable malignant hilar biliary obstruction: a multicenter randomized controlled trial, the TESLA RCT” 🔎
Ductular reaction is a feature of advanced MASLD, but its role in disease progression remains unclear.
💡 Hear #UEGWeek top abstract awardee Dania El Abyad discuss research exploring how it interacts with the immune microenvironment and relates to clinical outcomes.
💡 Hear #UEGWeek top abstract awardee Dania El Abyad discuss research exploring how it interacts with the immune microenvironment and relates to clinical outcomes.
October 20, 2026 at 7:04 AM
Ductular reaction is a feature of advanced MASLD, but its role in disease progression remains unclear.
💡 Hear #UEGWeek top abstract awardee Dania El Abyad discuss research exploring how it interacts with the immune microenvironment and relates to clinical outcomes.
💡 Hear #UEGWeek top abstract awardee Dania El Abyad discuss research exploring how it interacts with the immune microenvironment and relates to clinical outcomes.
October 18, 2026 at 6:05 PM
🔬 Early treatment, lasting benefits. Presented at #UEGWeek, five-year follow-up of the PROFILE trial showed improved long-term outcomes with early top-down anti-TNF therapy versus conventional step-up treatment in newly diagnosed Crohn’s disease.
See the findings at a glance!
See the findings at a glance!
October 20, 2026 at 9:00 AM
🔬 Early treatment, lasting benefits. Presented at #UEGWeek, five-year follow-up of the PROFILE trial showed improved long-term outcomes with early top-down anti-TNF therapy versus conventional step-up treatment in newly diagnosed Crohn’s disease.
See the findings at a glance!
See the findings at a glance!
💊 Unveiled at #UEGWeek, new research links antibiotic use from childhood through early adulthood to higher odds of IBS at age 24, with the odds increasing as prescriptions rose.
Read the full press release for the findings: https://bit.ly/4zG0csC
Read the full press release for the findings: https://bit.ly/4zG0csC
October 19, 2026 at 11:30 AM
💊 Unveiled at #UEGWeek, new research links antibiotic use from childhood through early adulthood to higher odds of IBS at age 24, with the odds increasing as prescriptions rose.
Read the full press release for the findings: https://bit.ly/4zG0csC
Read the full press release for the findings: https://bit.ly/4zG0csC
📣 Late-Breaking news!
Hear from #UEGWeek presenter Bas Groot Koerkamp as he discusses the study: Primary percutaneous stenting versus endoscopic drainage for unresectable malignant hilar biliary obstruction: a multicenter randomized controlled trial, the TESLA RCT ▶️
Hear from #UEGWeek presenter Bas Groot Koerkamp as he discusses the study: Primary percutaneous stenting versus endoscopic drainage for unresectable malignant hilar biliary obstruction: a multicenter randomized controlled trial, the TESLA RCT ▶️
October 19, 2026 at 10:00 AM
📣 Late-Breaking news!
Hear from #UEGWeek presenter Bas Groot Koerkamp as he discusses the study: Primary percutaneous stenting versus endoscopic drainage for unresectable malignant hilar biliary obstruction: a multicenter randomized controlled trial, the TESLA RCT ▶️
Hear from #UEGWeek presenter Bas Groot Koerkamp as he discusses the study: Primary percutaneous stenting versus endoscopic drainage for unresectable malignant hilar biliary obstruction: a multicenter randomized controlled trial, the TESLA RCT ▶️
Missed out on a chance for a HOT spot at #UEGWeek? Tomorrow (Tuesday) walk-in sessions are available at 10:00 and 12:30.
Full details here: www.esge.com/api/liv...
Full details here: www.esge.com/api/liv...
October 19, 2026 at 6:00 PM
Missed out on a chance for a HOT spot at #UEGWeek? Tomorrow (Tuesday) walk-in sessions are available at 10:00 and 12:30.
Full details here: www.esge.com/api/liv...
Full details here: www.esge.com/api/liv...
💧 A more efficient approach to colorectal ESD? A trial presented yesterday at #UEGWeek found underwater ESD was non-inferior to conventional ESD for en bloc resection, with shorter procedure times and less intraprocedural bleeding.
View our visual recap.
View our visual recap.
October 19, 2026 at 1:00 PM
💧 A more efficient approach to colorectal ESD? A trial presented yesterday at #UEGWeek found underwater ESD was non-inferior to conventional ESD for en bloc resection, with shorter procedure times and less intraprocedural bleeding.
View our visual recap.
View our visual recap.
Obligatory opening shot for #UEGWeek in Barcelona — I swear it’s getting harder to get it all in one photo every year! @myueg.bsky.social #GastroSky
October 18, 2026 at 10:22 AM
Obligatory opening shot for #UEGWeek in Barcelona — I swear it’s getting harder to get it all in one photo every year! @myueg.bsky.social #GastroSky
Presented today at #UEGWeek, the PEPPER trial compared three deprescribing strategies with similar success rates. At 1 year, 43.2% of participants were taking fewer than 4 PPI doses per month and were willing to continue this approach.
🔍 Explore our infographic!
🔍 Explore our infographic!
October 19, 2026 at 5:30 PM
Presented today at #UEGWeek, the PEPPER trial compared three deprescribing strategies with similar success rates. At 1 year, 43.2% of participants were taking fewer than 4 PPI doses per month and were willing to continue this approach.
🔍 Explore our infographic!
🔍 Explore our infographic!
❗ Are you attending #UEGWeek 2026? Join us on Tuesday 20th Oct (10:30-12:30), Room 8.38 for the #INFOGUT COST Action (CA23110): Integrating In Vitro #Models into Bedside-to-Bench Gut #Microbiota Research - Common Interest Group Meeting @myueg.bsky.social.👇 AMAZING SPEAKERS! 🤓 Open to EVERYONE!
October 18, 2026 at 8:27 PM
❗ Are you attending #UEGWeek 2026? Join us on Tuesday 20th Oct (10:30-12:30), Room 8.38 for the #INFOGUT COST Action (CA23110): Integrating In Vitro #Models into Bedside-to-Bench Gut #Microbiota Research - Common Interest Group Meeting @myueg.bsky.social.👇 AMAZING SPEAKERS! 🤓 Open to EVERYONE!
Less time, less intraprocedural bleeding and the same en bloc resection rate – new trial findings at #UEGWeek comparing underwater with conventional colorectal ESD.
🔍 Watch top abstract awardee Arianna Andreozzi unpack today’s results.
🔍 Watch top abstract awardee Arianna Andreozzi unpack today’s results.
October 18, 2026 at 3:30 PM
Less time, less intraprocedural bleeding and the same en bloc resection rate – new trial findings at #UEGWeek comparing underwater with conventional colorectal ESD.
🔍 Watch top abstract awardee Arianna Andreozzi unpack today’s results.
🔍 Watch top abstract awardee Arianna Andreozzi unpack today’s results.
Immune changes could signal IBD up to 10 years before diagnosis.
New research at #UEGWeek identified distinct antibody patterns before Crohn’s disease and ulcerative colitis diagnosis, suggesting potential for earlier risk detection.
🔍 Read more: https://bit.ly/4zKyTNU
New research at #UEGWeek identified distinct antibody patterns before Crohn’s disease and ulcerative colitis diagnosis, suggesting potential for earlier risk detection.
🔍 Read more: https://bit.ly/4zKyTNU
October 19, 2026 at 8:30 AM
Immune changes could signal IBD up to 10 years before diagnosis.
New research at #UEGWeek identified distinct antibody patterns before Crohn’s disease and ulcerative colitis diagnosis, suggesting potential for earlier risk detection.
🔍 Read more: https://bit.ly/4zKyTNU
New research at #UEGWeek identified distinct antibody patterns before Crohn’s disease and ulcerative colitis diagnosis, suggesting potential for earlier risk detection.
🔍 Read more: https://bit.ly/4zKyTNU
🔬 What role does ductular reaction play in MASLD? Research presented yesterday at #UEGWeek suggests its pro-inflammatory form may actively shape the liver’s immune microenvironment.
Read our bitesize recap.
Read our bitesize recap.
October 19, 2026 at 7:30 AM
🔬 What role does ductular reaction play in MASLD? Research presented yesterday at #UEGWeek suggests its pro-inflammatory form may actively shape the liver’s immune microenvironment.
Read our bitesize recap.
Read our bitesize recap.